Literature DB >> 25552725

Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells.

Elena Grabski1, Ilka Wappler2, Stephanie Pfaender2, Eike Steinmann2, Sibylle Haid2, Andrzej Dzionek3, Thomas Pietschmann4, Ulrich Kalinke5.   

Abstract

UNLABELLED: Worldwide, approximately 160 million people are chronically infected with hepatitis C virus (HCV), seven distinct genotypes of which are discriminated. The hallmarks of HCV are its genetic variability and the divergent courses of hepatitis C progression in patients. We assessed whether intragenotypic HCV variations would differentially trigger host innate immunity. To this end, we stimulated human primary plasmacytoid dendritic cells (pDC) with crude preparations of different cell culture-derived genotype 2a HCV variants. Parental Japanese fulminant hepatitis C virus (JFH1) did not induce interferon alpha (IFN-α), whereas the intragenotypic chimera Jc1 triggered massive IFN-α responses. Purified Jc1 retained full infectivity but no longer induced IFN-α. Coculture of pDC with HCV-infected hepatoma cells retrieved the capacity to induce IFN-α, whereas Jc1-infected cells triggered stronger responses than JFH1-infected cells. Since the infectivity of virus particles did not seem to affect pDC activation, we next tested Jc1 mutants that were arrested at different stages of particle assembly. These experiments revealed that efficient assembly and core protein envelopment were critically needed to trigger IFN-α. Of note, sequences within domain 2 of the core that vitally affect virus assembly also crucially influenced the IFN-α responses of pDC. These data showed that viral determinants shaped host innate IFN-α responses to HCV. IMPORTANCE: Although pegylated IFN-α plus ribavirin currently is the standard of care for the treatment of chronic hepatitis C virus infection, not much is known about the relevance of early interferon responses in the pathogenesis of hepatitis C virus infection. Here, we addressed whether intragenotypic variations of hepatitis C virus would account for differential induction of type I interferon responses mounted by primary blood-derived plasmacytoid dendritic cells. Surprisingly, a chimeric genotype 2a virus carrying the nonstructural genes of Japanese fulminant hepatitis C virus (JFH1) induced massive type I interferon responses, whereas the original genotype 2a JFH1 strain did not. Our detailed analyses revealed that, not the virus infectivity, but rather, the efficiency of virus assembly and core protein envelopment critically determined the magnitude of interferon responses. To our knowledge, this is the first example of hepatitis C virus-associated genetic variations that determine the magnitude of innate host responses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25552725      PMCID: PMC4337522          DOI: 10.1128/JVI.03229-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  Plasmacytoid dendritic cells--virus experts of innate immunity.

Authors:  Winfried Barchet; Marina Cella; Marco Colonna
Journal:  Semin Immunol       Date:  2005-08       Impact factor: 11.130

2.  Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection.

Authors:  Axel Ulsenheimer; J Tilman Gerlach; Maria-Christina Jung; Norbert Gruener; Martin Wächtler; Markus Backmund; Teresa Santantonio; Winfried Schraut; Malte H J Heeg; Carl A Schirren; Reinhart Zachoval; Gerd R Pape; Helmut M Diepolder
Journal:  Hepatology       Date:  2005-03       Impact factor: 17.425

3.  Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography.

Authors:  Astrid Zahn; Jean-Pierre Allain
Journal:  J Gen Virol       Date:  2005-03       Impact factor: 3.891

4.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.

Authors:  Randy S Longman; Andrew H Talal; Ira M Jacobson; Charles M Rice; Matthew L Albert
Journal:  J Infect Dis       Date:  2005-06-27       Impact factor: 5.226

5.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Authors:  Etienne Meylan; Joseph Curran; Kay Hofmann; Darius Moradpour; Marco Binder; Ralf Bartenschlager; Jürg Tschopp
Journal:  Nature       Date:  2005-09-21       Impact factor: 49.962

6.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

7.  Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms.

Authors:  Guofeng Cheng; Jin Zhong; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-17       Impact factor: 11.205

8.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Authors:  Thomas Pietschmann; Artur Kaul; George Koutsoudakis; Anna Shavinskaya; Stephanie Kallis; Eike Steinmann; Karim Abid; Francesco Negro; Marlene Dreux; Francois-Loic Cosset; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease.

Authors:  Anne M Wertheimer; Antony Bakke; Hugo R Rosen
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

10.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

View more
  7 in total

Review 1.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 2.  Immunopathogenesis of Hepatitis C Virus Infection.

Authors:  David E Kaplan
Journal:  Gastroenterol Clin North Am       Date:  2015-08-13       Impact factor: 3.806

Review 3.  Regulation of the Host Antiviral State by Intercellular Communications.

Authors:  Sonia Assil; Brian Webster; Marlène Dreux
Journal:  Viruses       Date:  2015-08-19       Impact factor: 5.048

4.  Hepatitis C Virus Stimulates Murine CD8α-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner.

Authors:  Stephanie Pfaender; Elena Grabski; Claudia N Detje; Nina Riebesehl; Stefan Lienenklaus; Eike Steinmann; Ulrich Kalinke; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2016-07-06       Impact factor: 6.823

5.  Human monocyte-derived macrophages inhibit HCMV spread independent of classical antiviral cytokines.

Authors:  Jennifer Becker; Volker Kinast; Marius Döring; Christoph Lipps; Veronica Duran; Julia Spanier; Pia-Katharina Tegtmeyer; Dagmar Wirth; Luka Cicin-Sain; Antonio Alcamí; Ulrich Kalinke
Journal:  Virulence       Date:  2018       Impact factor: 5.882

6.  Toll-like receptors matter: plasmacytoid dendritic cells in COVID-19.

Authors:  Jennifer Becker; Ulrich Kalinke
Journal:  EMBO J       Date:  2022-04-26       Impact factor: 14.012

7.  Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice.

Authors:  Wolfgang Koestner; Julia Spanier; Tanja Klause; Pia-K Tegtmeyer; Jennifer Becker; Vanessa Herder; Katharina Borst; Daniel Todt; Stefan Lienenklaus; Ingo Gerhauser; Claudia N Detje; Robert Geffers; Martijn A Langereis; Florian W R Vondran; Qinggong Yuan; Frank J M van Kuppeveld; Michael Ott; Peter Staeheli; Eike Steinmann; Wolfgang Baumgärtner; Frank Wacker; Ulrich Kalinke
Journal:  PLoS Pathog       Date:  2018-08-03       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.